Century Therapeutics
Developing novel allogeneic iPSC-derived natural killer (NK) and T cell products with the potential to overcome many limitations of earlier generation cell therapies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor investor | €0.0 Valuation: €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
* | $60.0m | Private Placement VC | |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | (57 %) | 195 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | (2333 %) | (4467 %) | (1626 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | (2518 %) | (6115 %) | (1921 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | 2061 % | 4148 % | 1628 % |
Source: Company filings or news article
Related Content
Century Therapeutics, Inc. is a pioneering biotechnology company focused on developing transformative allogeneic cell therapies. These therapies are designed to treat both hematological (blood-related) and solid tumor malignancies, addressing significant unmet medical needs in the healthcare sector. The company leverages a comprehensive allogeneic cell therapy platform that includes industry-leading induced pluripotent stem cells (iPSCs), advanced differentiation techniques to generate immune effector cells from iPSCs, and CRISPR-mediated precision gene editing.
Century Therapeutics operates primarily in the biotechnology and healthcare markets, serving patients with severe cancer conditions. The business model revolves around research and development (R&D) of innovative therapies, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated through partnerships, licensing agreements, and eventual commercialization of successful therapies.
Keywords: allogeneic cell therapies, hematological malignancies, solid tumors, iPSCs, CRISPR, biotechnology, immune effector cells, cancer treatment, R&D, healthcare.
Tech stack
Investments by Century Therapeutics
Edit